Treatment of Mild and Moderate Alzheimer's Disease

Abstract

The present invention relates to methods of treatment using [3-(4-{2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1H-imidazol-4-yl}-phenoxy)-propyl]-diethyl amine (“COMPOUND I”) or a pharmaceutically acceptable salt thereof. In various embodiments, the methods of treatment include treatment of mild-to-moderate dementia of Alzheimer's type, diabetes, insomnia, and other indications. The present invention also relates to pharmaceutical compositions comprising COMPOUND I or a pharmaceutically acceptable salt thereof.

We claim: 
     
         1 . A method for treating diabetes comprising administering to a subject in need thereof an amount less than 20 mg per day of [3-(4-{2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1H-imidazol-4-yl}-phenoxy)-propyl]-diethyl amine or a pharmaceutically acceptable salt thereof. 
     
     
         2 . The method of  claim 1 , wherein the [3-(4-{2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1H-imidazol-4-yl}-phenoxy)-propyl]-diethyl amine is administered in a dose ranging from about 1 to about 20 mg per day. 
     
     
         3 . A method for inhibiting the reduction of glucose metabolism associated with the regression of subjects with mild-to-moderate Alzheimer's disease, comprising administering to a subject in need thereof an amount less than 20 mg per day of [3-(4-{2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1H-imidazol-4-yl}-phenoxy)-propyl]-diethyl amine or a pharmaceutically acceptable salt thereof. 
     
     
         4 . The method of  claim 3 , wherein the dose is about 5 mg per day or about 4 mg per day or about 3 mg per day or about 2 mg per day. 
     
     
         5 . The method of  claim 3 , wherein the method of treatment further comprises administering to the subject an acetylcholinesterase inhibitor (AChEI). 
     
     
         6 . The method of  claim 5 , wherein the AChEI is selected from the group consisting of donepezil hydrochloride, galantamine hydrochloride, rivastigmine tartrate, and tacrine hydrochloride. 
     
     
         7 . The method of  claim 3 , wherein the method of treatment further comprises administering to the subject memantine hydrochloride. 
     
     
         8 . The method of  claim 1 , wherein treatment of diabetes comprises lowering blood glucose levels in the subject. 
     
     
         9 . The method of  claim 8 , wherein the subject is suffering from mild-to-moderate Alzheimer's Disease. 
     
     
         10 . The method of  claim 8 , wherein the subject's blood glucose levels are reduced by at least 5 mg/dl. 
     
     
         11 . The method of  claim 8 , wherein the subject's naïve glucose level is greater than 100 mg/dl.